This proposal describes plans for the continuation of a research program involving synthesis, computer modeling, mechanistic/mode of action, biological, and spectroscopic studies focused on compounds of demonstrated or potential importance in cancer research and chemotherapy. It is the objective of this program to develop fundamentally new methods and strategies for the synthesis of such compounds, to elucidate the structural basis for their mode of action, and to test and exploit these new findings in the rational design of new cancer chemotherapeutic agents or compounds of interest in cancer research. Five projects are proposed for investigation during the continuation period. A major continuation study focusing on taxol, a promising chemotherapeutic agent recently approved for the treatment of ovarian and metastatic breast cancers, will be directed at the development of practical syntheses of taxol and its analogs, the elucidation of its molecular mode of action, and at the design of simplified, potentially superior clinical candidates. A second major project is directed at the continuation of our studies on novel DNA cleaving reagents and potential chemotherapeutic agents, focusing on a highly potent and readily synthesized new class of dynemicin analogs and on new classes of DNA cleaving agents that operate through the inducible generation of aryl radicals. A third major effort is directed at the elucidation of the molecular mode of action and the synthesis of simplified analogs of the highly potent marine natural product bryostatin, an exceptionally promising cancer chemotherapeutic agent now in clinical trials for the treatment of solid tumors. A fourth project is directed at the synthesis and evacuation of a new class of bioresponse modulators that induce the synthesis and expression of tumor associated antigens in human breast cancer cells, an activity that could be exploited in enhancing the performance of monoclonal-drug conjugates in cancer chemotherapy. A fifth project seeks to establish an understanding of the structural and functional role of RACKs (receptors for activated C kinases), a newly discovered class of proteins of fundamental importance in cellular signal transduction and new targets for the design of novel cancer chemotherapeutic agents. Overall, this research program is expected-to be of significant value in chemistry, biology, and medicine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031845-19
Application #
2894537
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Lees, Robert G
Project Start
1981-07-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
19
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Stanford University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
McKinlay, Colin J; Benner, Nancy L; Haabeth, Ole A et al. (2018) Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc Natl Acad Sci U S A 115:E5859-E5866
Fernandes-Cunha, Gabriella M; McKinlay, Colin J; Vargas, Jessica R et al. (2018) Delivery of Inorganic Polyphosphate into Cells Using Amphipathic Oligocarbonate Transporters. ACS Cent Sci 4:1394-1402
Yang, Hao; Staveness, Daryl; Ryckbosch, Steven M et al. (2018) REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment. ACS Cent Sci 4:89-96
Haabeth, Ole A W; Blake, Timothy R; McKinlay, Colin J et al. (2018) mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A 115:E9153-E9161
Khan, Tapan K; Wender, Paul A; Alkon, Daniel L (2018) Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents. J Cell Physiol 233:1523-1534
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Albert, Brice J; Niu, Austin; Ramani, Rashmi et al. (2017) Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep 7:7456
Ryckbosch, Steven M; Wender, Paul A; Pande, Vijay S (2017) Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nat Commun 8:6
McKinlay, Colin J; Vargas, Jessica R; Blake, Timothy R et al. (2017) Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A 114:E448-E456
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 90 publications